Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Durvalumab Being Explored in Real-World Setting of Locally Advanced Stage III NSCLC

May 21st 2019

Nicolas Girad, MD, discusses the importance of evaluating durvalumab in a real-world setting, other questions that remain unanswered in this area, and the role of immunotherapy in patients with non–small cell lung cancer.

Frontline Afatinib Shows Promise in EGFR+ NSCLC

May 21st 2019

Antonio Passaro, MD, PhD, discusses findings from a phase IIIb trial for patients with EGFR mutation-positive non–small cell lung cancer and discussed results from other studies investigating ALK and KRAS mutations in patients with NSCLC.

Dr. Nadler on the Impact of Immunotherapy in Squamous NSCLC

May 20th 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the impact of immunotherapy in squamous non–small cell lung cancer.

Clinical Utility of Tumor Mutational Burden Remains in Flux

May 20th 2019

Although study findings have identified tumor mutational burden as an important factor in responses to cancer therapy, establishing a definition for expression of this biomarker and harmonizing assays to measure it have proved challenging.

Pembrolizumab Approval in Squamous NSCLC Expands Treatment Arsenal

May 17th 2019

Viola W. Zhu, MD, PhD, explains how the use of immunotherapy has improved survival for patients with advanced squamous cell non–small cell lung cancer.

Dr. Banna on the Potential for CAR T-Cell Therapy in Lung Cancer

May 17th 2019

Giuseppe L. Banna, MD, consultant, Medical Oncology, Cannizzaro Hospital, discusses the potential for CAR T-cell therapy in the treatment of patients with lung cancer.

Strategies Evolve for Overcoming EGFR-TKI Resistance in NSCLC

May 17th 2019

Lyudmila A. Bazhenova, MD, sheds light on initial treatment approaches for patients with EGFR-mutant NSCLC and adapted therapeutic strategies at the time of progression.

Dr. Langer Discusses the Impact of Targeted Therapy in NSCLC

May 15th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of targeted therapy in non–small cell lung cancer.

How a NSCLC Pioneer Helped Unravel the Mysteries of EGFR

May 15th 2019

A 2018 Giants of Cancer Care award winner for Lung Cancer, Bruce E. Johnson, MD, has helped define the genomic era in lung cancer care. His notable contributions include characterizing the role that EGFR mutations play in non–small cell lung cancer.

Dr. Mason on Progress Made in Resectable Stage III Lung Cancer

May 15th 2019

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Health, chief of lung transplantation, head of the Department of Thoracic Surgery, Baylor University Medical Center, discusses the progress that has been made in resectable stage III lung cancer.

TLR Agonists Emerge as Potential New Partner for Checkpoint Inhibitors

May 15th 2019

Toll-like receptors, a group of proteins that are components of innate immunity, are emerging as promising targets in a new wave of immunotherapies under development.

Dr. Kelly on the Outlook of ALK-Positive NSCLC

May 14th 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the 10 Baylor Scott & White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the outlook of patients with ALK-positive non–small cell lung cancer (NSCLC).

Importance of Quality of Life Endpoints in Clinical Trials

May 10th 2019

Massimo Di Maio, PhD, medical oncologist, Mauriziano Hospital, professor of medical oncology, University of Turin, discusses the importance of quality of life (QoL) endpoints in clinical trials.

Dr. Zhu on Primary Resistance to Osimertinib in EGFR-Mutant NSCLC

May 8th 2019

You-cai Zhu, MD, PhD, Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, discusses primary resistance to osimertinib (Tagrisso) in EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Bauml on Locally Ablative Therapy in Oligometastatic NSCLC

May 8th 2019

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the use of locally ablative therapy in patients with oligometastatic non–small cell lung cancer.

Dr. Liu on the Potential of Pembrolizumab in SCLC

May 8th 2019

Stephen Liu, MD, associate professor of medicine, Division of Hematology and Oncology, Georgetown University Medical Center, discusses the potential of pembrolizumab in the treatment of patients with small cell lung cancer.

Dr. Kelly Discusses the Treatment of Patients With ALK+ NSCLC

May 7th 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott and White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the treatment of patients with ALK-positive non–small cell lung cancer.

Dr. Stahel on Treatment Sequencing in Stage IV NSCLC

May 3rd 2019

Rolf A. Stahel, MD, professor in the oncology clinic, University Hospital, Zurich, discusses treatment sequencing in stage IV non–small cell lung cancer.

Dr. Addeo Discusses the Need for Biomarkers in NSCLC

May 3rd 2019

Alfredo Addeo, MD, consultant medical oncologist, University Hospital of Geneva, discusses the need for effective biomarkers in non–small cell lung cancer.

Unanswered Questions With the Role of TMB in NSCLC

May 3rd 2019

Umberto Malapelle, PhD, assistant professor, University of Naples Federico II, discusses unanswered questions regarding the role of tumor mutational burden in non–small cell lung cancer.